ARS Pharmaceuticals (SPRY) Change in Accured Expenses (2020 - 2026)

ARS Pharmaceuticals has reported Change in Accured Expenses for 7 years, with the latest figure at $10.3 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 147.48% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.0 million (up 30.1% YoY) and the FY2025 annual result came in at $18.9 million, up 15.04% from the prior year.
• Change in Accured Expenses grew to $10.3 million in Q1 2026 per SPRY's latest filing, from -$9.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $12.8 million in Q2 2025 and troughed at -$11.4 million in Q4 2022.
• A 5-year average of $1.9 million and a median of $1.3 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses soared 1268.75% in 2024, then slumped 218.27% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$11.4 million in 2022, then gained by 22.25% to -$8.9 million in 2023, then soared by 186.3% to $7.7 million in 2024, then plunged by 218.27% to -$9.1 million in 2025, then jumped by 213.8% to $10.3 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $10.3 million, -$9.1 million, and $11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.